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Atrial Fibrillation: Disclosures 
Stroke Prevention in Atrial Fibrillation:  
Learning Objectives 
1. Describe the characteristics of the population needing 
stroke prevention in chronic atrial fibrillation 
 
2. Review the comparative effectiveness of oral 
anticoagulant therapeutic options, benefits and risks 
 
3. Explore issues of effectiveness, safety and value  
from a population health perspective 
 
 
 
Outcomes Research:  The Purpose 
To determine:  
  Do patients benefit? 
 Warfarin works, but sub-optimally for many 
 New trials and designs (NOACs…) 
  What treatments work best? 
 Evaluating opportunities for optimal use 
 Considering implications of RE-LY, ROCKET, 
ARISTOTLE, and Real World Studies… 
  Are health-care resources well spent? 
Agency for Health Care Policy & Research, 1990 
Agency for Healthcare Research and Quality, 2003 
Atrial Fibrillation (AF):  
Morbidity and Mortality 
•  ~15% of all strokes occur in people with AF 
 
• Risk of stroke in untreated AF patients averages ~ 5% /yr 
 
• Risk of stroke in AF patients by age group 
– 1.5% in 50 to 59 year age group 
– 23.5% in 80 to 89 year age group 
 
• AF is associated with a 50 to 90% increase in risk of 
 death after adjustment for coexisting CV conditions 
Wolf PA, et al. Stroke 1991; 22: 983-988                                   
Benjamin EB, et al. Circulation 1998;98:946-952.                    
American Heart Association.  Heart Disease and Stroke Statistics-2006 Update. Dallas, TX: American Heart Association;2006.  
Projected Number of Persons with AF in the 
U.S. between 2000 and 2050  
Assumes no further increase in age-adjusted AF incidence (yellow curve) and assumes a 
continued increase in incidence rate as evident in 1980 to 2000 (red curve) 
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Source: Miyasaka Y, et.al. Circulation 2006;114:119-125.   
Efficacy and Effectiveness 
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Source: Fletcher, 
Fletcher,Wagner1988 
Historical Efficacy of warfarin in  
Atrial Fibrillation 
Five Randomized Trials in Non-Rheumatic AF 
Study            Warfarin (#)    Cont. (#) INR     RR p-Value 
AFASAK 335        336  2.8-4.2  60%   0.027 
SPAF  210        211  2.0-4.5  67%   0.01 
BAATAF 212        208  1.5-2.7  86% <0.05 
CAFA*  187        191  2.0-3.0  45%   0.25 
SPINAF  260       265  1.4-2.8  79%   0.001 
*  Stopped early due to published positive results  
68% overall risk reduction for stroke 
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Source: Granger S, MacMurray J. JACC 2006;48:434-7; and Michael Hanna, MD. 
Relative Effects of Various CV Therapies 
Trends in Warfarin Use and Therapeutic Outcomes  
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2006;37:1969-1974. Treatment would prevent 40,000 strokes per year. 
36% 
 AF patients with no identified contraindications  
not anticoagulated despite moderate or high risk  
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Warfarin Liabilities 
• Narrow therapeutic range (2.0-3.0). 
 
• Food effect and multiple drug and botanical interactions 
 
• Need for therapeutic monitoring. 
 
• INR of warfarin patients is in the therapeutic range only ~60% 
    of the time, in trials. 
 
• Risk of intracranial hemorrhage, particularly in the elderly. 
 
• Warfarin is a leading cause of adverse drug events 
    and ER visits. 
 
Source: Elaine M. Hylek, MD, MPH, Associate Professor of Medicine, Boston University 
Factors Influencing Warfarin Under-Use  
1. Lack of consensus on perceived or actual barriers to use: 
e.g., fall risk, prior bleeding, concurrent medicine use, 
ETOH… 
 
2. Suboptimal candidacy for anticoagulant therapy  
e.g., comorbidities, polypharmacy, non-adherence… 
 
3. Barriers to INR monitoring-dependence on caregivers,    
logistical constraints, cost, hassle 
 
4.    Inability to tolerate therapy long-term 
 
 
Source: Elaine M. Hylek, MD, MPH, Associate Professor of Medicine, Boston University 
Adherence to Quality Indicators: Conditions 
            Condition    % 
 
• Breast cancer    76 
• Prenatal care    73 
• Hypertension    65 
• CHF      64 
• Depression     58 
• Asthma     53 
• Diabetes mellitus    45 
• Atrial fibrillation    25 
• Hip fracture     23 
• Alcohol dependence   11  
Source: McGlynn EA, et.al. NEJM  2003;348:2635-45. 
Perceived or Actual Barriers to Warfarin Use in Atrial 
Fibrillation Based on Electronic Medical Records 
M. Rosenman,1,2 T. Simon,3 E. Teal,1 P. McGuire,1 D. Nisi,1 J. Jackson4 
 
1 Regenstrief Institute, Inc., Indianapolis, Indiana, USA 
2 Indiana University School of Medicine, Indianapolis, Indiana, USA 
3 Bristol-Myers Squibb, Lawrenceville, NJ, USA 
4 Thomas Jefferson University, Philadelphia, PA, USA 
 
Presented: European Society of Cardiology, 2009  
         American Heart Association, 2009 
Published: American Journal of Therapeutics, 2012;19:330-337. 
This study was funded by Bristol-Myers Squibb and Pfizer Inc.  
Methods: Study Population 
• Inclusion criteria 
– New-onset NVAF between 1998 and 2007 
•Defined as first encounter (hospital or office visit)  
with AF stored in the RMRS 
 
• Exposure: Warfarin (vitamin K antagonist [VKA]) 
– Hospital/Clinic pharmacy transaction records 
or 
– Physician Order Entry System (Gopher)1 
•An electronic version of a prescription 
 
1McDonald CJ, Tierney WM. The Medical Gopher—a microcomputer system to help find, organize and decide about patient data. 
West J Med 1986;145:823-9. 
Source: Rosenman, ESC and AHA 2009 
Methods: Identification of Barriers 
• Perceived or actual barriers to warfarin use: 
– Alcohol abuse (ETOH) 
– Cirrhosis/Hepatitis 
– Intracranial hemorrhage 
– Gastrointestinal or genitourinary hemorrhage  
– Other hemorrhage 
– Predisposition to falls (Falls) 
– Renal insufficiency (RI) 
      any time before or on the AF index date 
• ICD9 codes 
• RMRS dictionary terms (Gopher system has  
drop-down menus with diagnoses, etc) 
Source: Rosenman, ESC and AHA 2009 
Methods: Risk Adjustments 
HASBLED & CHADS-VASc: Apps – MedCalc 2.5, P Pfiffner  
Odem LE, et.al. Pharmacotherapy 2012;32(3):285-296 
Risk Score / Factor (points) CHADS2 CHA2DS2 – VASc  
Congestive heart failure 1 1 
Hypertension 1 1 
Age > 75 years 1 2 
Diabetes mellitus 1 1 
Prior Stroke or TIA 2 2 
Vascular disease (Previous MI, 
PAD, aortic plaque) 
1 
Age (65-74) 1 
Sex category (female) 1 
NVAF 
N=3329 
Warfarin 
N=1502 (45%) 
No warfarin 
N=1827 (55%) 
No Barriers 
N=847 (56%) 
Barriers 
N=655 (44%) 
No Barriers 
N=938 (51%) 
Barriers 
N=889 (49%) 
Results: Perceived or Actual Barriers by 
Exposure to Warfarin by CHADS2 Score 
CHADS=0 
CHADS=1 
CHADS=2+ 
578 (17%) 
854 (26%) 
1897 (57%) 
CHADS=0 
CHADS=1 
CHADS=2+ 
197 (13%) 
383 (26%) 
922 (61%) 
CHADS=0 
CHADS=1 
CHADS=2+ 
141 (17%) 
239 (28%) 
467 (55%) 
CHADS=0 
CHADS=1 
CHADS=2+ 
56 (9%) 
144 (22%) 
455 (70%) 
CHADS=0 
CHADS=1 
CHADS=2+ 
381 (21%) 
471 (26%) 
975 (53%) 
CHADS=0 
CHADS=1 
CHADS=2+ 
250 (27%) 
280 (30%) 
408 (44%) 
CHADS=0 
CHADS=1 
CHADS=2+ 
131 (15%) 
191 (21%) 
567 (64%) 
                Source: Rosenman, ESC and AHA 2009 
49% 51% 
Results:  How long before the AF index date was 
the most recent record of the barrier?   
(N=599 exposed to warfarin, and with CHADS2 > 0) 
ETOH
44%45%
10%
GI/GU Hemorrhage
50%
11%
39%
Predisposition to Falls
58%
16%26%
Cirrhosis/Hepatitis
6%
31%
63%
Renal Insufficiency
19%
7%74%
Within the past 60 days 61-364 days A year or more ago 
Source: Rosenman, ESC and AHA 2009 
Outcomes Research:  The Purpose 
To determine:  
  Do patients benefit? 
 Warfarin works – RCTs = 68 % Relative Risk Reduction 
(RRR) of Strokes 
 But in the REAL WORLD 
 ~40 % UNTREATED 
 ~27 %  GOOD QUALITY OF CARE 
 Many BARRIERS to effective care 
 REAL or IMAGINED 
Agency for Health Care Policy & Research, 1990 
Agency for Healthcare Research and Quality, 2003 
Current Trials of Antithrombotic Therapy for  
Stroke Prevention in Atrial Fibrillation 
Trial Agent Blind CHADS Size  
RE-LY Dabigatran OL ≥ 1 18,000  
ROCKET Rivaroxaban DB  ≥ 2-3  14,000  
ARISTOTLE Apixaban DB  ≥ 1  15,000  
ENGAGE Endoxaban DB ≥ 2 20,000  
Total    66,000 
Warfarin-Control 
Phase III 
AF Historical trials: 3,763 
AF Trials: Key Design Issues 
 
•  Superiority vs. non-inferiority? 
•  Non-inferiority margin 
•  Open-label (PROBE) vs. double-blind (DB)? 
•  Dosing issues for benefit, for risk (e.g. renal) 
•  Benefit-risk tolerances 
•  Extrapolations for populations at risk  
 
See: Jessica Mega’s NEJM (28 Aug 11) editorial and 
Kevin Jackson’s AHJ (2008) article! 
1.  Dabigatran 150 mg, BID 
2.  Dabigatran 110 mg, BID 
3.  Warfarin INR 2 to 3 range 
Connolly S, et al NEJM 2009;361:1139-1151 
RE-LY 
Courtesy: Dr. G Merli 
Patel M et al, NEJM 2011;365:883-891 
ROCKET AF 
Rivaroxaban 20 mg, Qday 
Warfarin INR 2-3 Range 
  
Courtesy: Dr. G Merli 
  
Granger C, et al NEJM 2011;365:981-992 
Apixaban 5 mg, BID 
Warfarin INR 2 - 3 
ARISTOTLE 
Courtesy: Dr. G Merli 
Comparison of Oral Anticoagulants* 
Generic 
name 
warfarin dabigatran rivaroxiban apixaban 
Brand name Coumadin Pradaxa Xarelto Eliquis 
Half-Life 
(hours) 
40  12-14 7-10 12  
Renal 
Clearance % 
0 80 35 25 
Dose Once a day Twice a day Once a day Twice a day 
Approx 
$/pill 
 
$0.64 
 
$4.37 bid 
 
$8.75 
 
>$4.50 bid 
*Granger and Armaganijan, Circ 2012;125:159-64. 
  Bilazarian, theheart.org, July 5, 2012. 
Comparison of oral anticoagulants – baseline* 
 
Baseline Data 
 
warfarin 
 
dabigatran 
 
rivaroxiban 
 
apixaban 
Trials 5 major 
trials 
RE-LY, 
 NEJM 2009 
ROCKET, 
NEJM 2011 
ARISTOTLE, 
NEJM 2011 
Age (years) 71 73 70 
CHADS2 (mean) 
 
2.2 3.5 2.1 
CHADS2 3-6 (%) 32 87 30 
Prior stroke (%) 20 55 19 
Prior warfarin (%) 50 62 57 
* Lip GYH, et.al. JACC 2012;60:738-46. 
Comparison of oral anticoagulants – outcomes* 
warfarin dabigatran 
(150 mg) 
rivaroxiban apixaban 
Trial Results 
(P) 
Versus  
placebo-asa 
Versus  
warfarin 
Versus 
warfarin 
Versus  
warfarin 
Stroke or 
systemic emb 
1.4 v. 4.7   1.11 v. 1.71 2.12 v. 2.42 1.27 v. 1.60  
Hemorrhagic 
stroke 
  0.1 v. 0.38  0.5 v. 0.7  0.24 v. 0.47  
Ischemic stroke 0.92 v. 1.20  NR 0.97 v. 1.05 
Major bleeding 
(on treatment) 
1.6 v. 1.0  
  
3.11 v. 3.36 3.6 v. 3.45 2.13 v. 3.09  
All cause death 3.64 v. 4.13 4.5 v. 4.9 3.52 v. 3.94  
* Granger and Armaganijan, Circ 2012;125:159-64. 
  Lip GYH, et.al. JACC 2012;60:738-46. 
Annual Incidence – rate per 100 person-years 
NR – not reported 
Comparison of oral anticoagulants – % RRR* 
warfarin dabigatran 
(150 mg) 
rivaroxiban apixaban 
Trial Results 
(RRR; P) 
Versus  
placebo-asa 
Versus  
warfarin 
Versus 
warfarin 
Versus  
warfarin 
Stroke or 
systemic emb 
68 %  34 %  12 % 21 %  
Hemorrhagic 
stroke 
74 %      41 %  49 %  
Ischemic stroke  24 %     6 % 8 % 
Major bleeding   7 % 104 %  31 %  
All cause death 12 %     8 %  11 %  
* Granger and Armaganijan, Circ 2012;125:159-64. 
  Lip GYH, et.al. JACC 2012;60:738-46. 
Relative Risk Reduction (RRR) 
Caveats Relating to Published Trials 
Concerning Hemorrhage 
Randomized trials 
 - Enrolled few patients ≥ 80 years 
 - Highly selected, closely monitored 
 - Vitamin K antagonist at entry 
 
Prospective cohort studies 
 - Predominantly non-inception cohort studies 
  of prevalent warfarin use (survivor bias)  
 - Enrolled few patients ≥ 80 years 
 - Varying definitions of bleeding 
Danger Ahead:  
Watch Out for Indirect Comparisons!*  
• Use Extreme Caution – e.g. Fibrinolytics misleading 
• Potential Mitigating Issues with Anticoagulants: 
• Trial designs 
• Event rates (e.g. MI and Bleeding) 
• CHADS2 Risk Cohorts 
• INR – TTR (Time in Therapeutic Range) 
• Regulatory Considerations, for example: 
• Dabigatran - 110 mg not approved  
• bleeding vs. warfarin - similar 
• Rivaroxiban - Stroke and bleeding vs. warfarin  - similar 
• Apixaban - Mortality vs. warfarin - superior 
* Cannon and Kohi, JACC 2012;60:747-8 
Pooled Indirect Comparisons: 
DABI, RIVA and APIX versus Warfarin* 
Stroke or Systemic Embolism   21% (p<0.001) 
Stroke       23% (p<0.001) 
Hemorrhagic Stroke    53% (p<0.001) 
All Cause Mortality              12% (p<0.001) 
Major Bleeding      13% (p<0.001) 
 
* Lip GYH et.al, JACC 2012;60:738-46 
Indirect Comparisons: CAUTION 
  Lip GYH, et al. JACC 2012;60:738-746 
 
• Stroke / sys emb:  DABI better RIVA (by 26%)  
• Ischemic stroke, no significant differences 
• Major bleeding: APIX < DABI150  26%; < RIVA  34%; = DABI110 
• No profound significant differences in efficacy 
• safety – better for APIX or DABI110 
 Schneeweiss S, et al. Circ CV Qual Outcomes 2012;5:480-486 
 
• CHADS2 ≥ 3 – ADJUSTMENT:  DABI 150  vs. APIX  vs.  RIVA 
• For efficacy, no significant differences 
• although DABI & APIX numerically better RIVA 
• For major hemorrhage,  APIX less than DABI or RIVA 
• Until head-to-head trials, adjusted indirect comparisons are one  
tool to guide initial therapeutic choices   
 
 
Outcomes Research:  The Purpose 
To determine:  
  What treatments work best? 
 RCT EVIDENCE: RE-LY, ROCKET-AF, ARISTOTLE 
 NOACs superior to warfarin 
 First viable alternatives in 50 years  
 Real World Studies ???? 
 Usual Care: Safety and Effectiveness 
 Monitoring 
 Cost 
Agency for Health Care Policy & Research, 1990 
Agency for Healthcare Research and Quality, 2003 
Recent Literature: Commentaries 
 Ansell J, Circ 2012;125:165-170 
 
• Time in Therapeutic Range is important to effectiveness 
• Short T½, has implications for adherence and stroke risk 
• No monitoring has implications for safety 
• No antidote for emergent situations 
• Cost 
 
 Spinler SA and Shafir V, Circ 2012;126:133-137 
 
• Pharmacy perspective; case study approach; easy read 
• P-450 system and CYP3A4 metabolic implications 
• Drug-drug interactions, renal disease adjustments 
• Switching therapies 
• Combined use of other anticoagulants (UFH, LMWH…) 
Novel Anticoagulant Comparison 
Dabigatran Rivaroxaban Apixaban 
Dialyzable Yes Probably Not Probably Not 
Protein Binding 35% >90% 87% 
Reversing Agent No Possibly  Possibly 
Erikkson BI, et al. Clin Pharmacokinet 2009;48:1-22. 
Courtesy: Dr. G Merli 
 Eerenberg E, et al Circulation 2011;124:1573-1579 
Courtesy: Dr. G Merli 
Package Insert Recommendations 
•Dabigatran 
– FFP, Prothrombin Complex Concentrate 
– Activated Factor VII 
– Dialysis 
 
•Rivaroxaban and Apixaban 
– Prothrombin Complex Concentrate 
– FFP 
Courtesy: Dr. G Merli 
AF Evidence: Key Practice Issues 
•  Well controlled vs. usual care? 
•  Controlling barriers to effective care: 
•  Patient medical characteristics (elderly…) 
•  Patient capabilities (logistics…) and comprehension 
(instructions, risk…)  
•  Systems (MD/office logistics, testing, $, legal…) 
•  Therapeutic motivations (Pt/Carer/MD/RN/PharmD) 
•  Net clinical benefit - tradeoffs? 
•  For the patient…, For the family… 
•  For the providers…, For the system… 
– Value assessments, for whom… 
Source: Ingelgard A, et al. J Thromb Thrombolysis. 2006;21(3):257-265 
Outcomes Research:  The Purpose 
To determine:  
 Are health-care resources well spent? 
 Cost Offsets 
 REAL WORLD Scenarios 
 Concluding thoughts 
Agency for Health Care Policy & Research, 1990 
Agency for Healthcare Research and Quality, 2003 
Comparison of Oral Anticoagulants – continued* 
warfarin dabigatran rivaroxiban apixaban 
Ischemic Stroke  490 373 461 451 
Hemorrhagic 
stroke 
225 59 133 115 
Systemic emb 40 38 17 33 
MI 292 371 237 257 
Major bleed 998 1030 1106 715 
CRN-M bleed 38 35 41 26 
TOTAL 2084 1905 1995 1599 
Savings vs 
warfarin 
----- 179 89 485 
* Deitelzweig, S, et.al. Ochsner Clinic, New Orleans, LA,  American College of Cardiology, April, 2012, Chicago, IL. 
Average medical costs in $/patient/year 
CRN-M Bleed – Clinically relevant non-major bleed 
Intervention Scenarios Representing  
Actual Practice Management / Outcomes*  
*Estimated from literature, see notes 
 
CEA v. warfarin, plus : ✚  Potential for positive findings 
The CLOT BLOG on theheart.org 
Samuel Z. Goldhaber, MD 
Professor of Medicine, Harvard Medical School 
Director, Venous Thromboembolism Research Group 
Co-Director, Anticoagulation Management Service 
Cardiovascular Division, Brigham and Women's Hospital, Boston, MA  
FDA approval of the latest NOAC for 
stroke prevention in AF: The "tipping 
point" for novel oral anticoagulants 
January 11, 2013 
Concluding Thoughts 
•Effective drugs are usually cost-effective 
• Well-controlled trials suggest superiority of NOACs, BUT… 
• Real world experience is needed! Issues to watch:  
– Non-trial subjects (elderly, renal, falls…)  
– Emergent situations (bleeding and risk)  
– Usual Care:  Adherence, DDIs, dosing, switching…  
– Afib and ACS (WOEST at ESC 2012) 
• clopidogrel + warfarin  >  aspirin + clopi + warf  
– yielded better efficacy and less bleeding 
•Other uses: Surgery-medical VTEp, DVT, PE, ACS and valves? 
 
Please fill out your evaluation 
Thank You! 
 
 
To listen to Forum podcasts visit Jefferson Digital Commons at: 
http://jdc.jefferson.edu/hpforum/.  
You also are welcome to post your comments regarding the 
Forums in this section of Jefferson Digital Commons.  
